{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:15:41Z","timestamp":1773962141315,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pathol.2025.10.008","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:23:50Z","timestamp":1769559830000},"page":"325-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of minimum inhibitory concentration with outcome in patients with Stenotrophomonas maltophilia bacteraemia treated with empirical levofloxacin"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3339-7281","authenticated-orcid":false,"given":"Jinghao Nicholas","family":"Ngiam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7374-8207","authenticated-orcid":false,"given":"Matthew Chung Yi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Michael","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4654-6434","authenticated-orcid":false,"given":"Ka Lip","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.10.008_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12879-025-10636-9","article-title":"Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024","volume":"25","author":"Koh","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.pathol.2025.10.008_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4931501","article-title":"Clinical features, outcomes, and risk factors of bloodstream infections due to Stenotrophomonas maltophilia in a tertiary-care hospital of China: a retrospective analysis","volume":"2019","author":"Chen","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.pathol.2025.10.008_bib3","article-title":"Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"10","author":"Banar","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pathol.2025.10.008_bib4","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2025.10.008_bib6","series-title":"CLSI M100: performance standards for antimicrobial susceptibility testing","year":"2023"},{"key":"10.1016\/j.pathol.2025.10.008_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jac\/dkab344","article-title":"Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision","volume":"77","author":"Fratoni","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2025.10.008_bib8","doi-asserted-by":"crossref","first-page":"dlac040","DOI":"10.1093\/jacamr\/dlac040","article-title":"Clinical challenges treating Stenotrophomonas maltophilia infections: an update","volume":"4","author":"Mojica","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.pathol.2025.10.008_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0732-8893(98)00089-3","article-title":"Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia","volume":"32","author":"Carroll","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.pathol.2025.10.008_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02705-21","article-title":"Activity of delafloxacin and levofloxacin against Stenotrophomonas maltophilia at simulated plasma and intrapulmonary pH values","volume":"10","author":"Vialichka","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.pathol.2025.10.008_bib11","doi-asserted-by":"crossref","first-page":"fnw145","DOI":"10.1093\/femsle\/fnw145","article-title":"In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression","volume":"363","author":"Pompilio","year":"2016","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.pathol.2025.10.008_bib12","series-title":"Guidance on Stenotrophomonas maltophilia","year":"2024"},{"key":"10.1016\/j.pathol.2025.10.008_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cmi.2018.11.008","article-title":"Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis","volume":"25","author":"Ko","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pathol.2025.10.008_bib14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/antibiotics10101226","article-title":"Antimicrobial treatment strategies for Stenotrophomonas maltophilia: a focus on novel therapies","volume":"10","author":"Gibb","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.pathol.2025.10.008_bib16","doi-asserted-by":"crossref","first-page":"e01809","DOI":"10.1128\/AAC.01809-20","article-title":"Pharmacokinetic and pharmacodynamic profiling of minocycline for injection following a single infusion in critically ill adults in a phase IV open-label multicenter study (ACUMIN)","volume":"65","author":"Lodise","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.10.008_bib17","article-title":"Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.10.008_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2025.10.008_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01433-20","article-title":"Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526003466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526003466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:12:54Z","timestamp":1773951174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302526003466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0031302526003466"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.10.008","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of minimum inhibitory concentration with outcome in patients with Stenotrophomonas maltophilia bacteraemia treated with empirical levofloxacin","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}